TABLE 3.
HLA allele | HIV-2+ (n) | HIV negative (n) | All (n) | P | OR | 95% CI |
---|---|---|---|---|---|---|
A*01 | 12.3 (18) | 14.0 (42) | 13.5 (60) | 0.58 | 0.84 | 0.45-1.56 |
A*02 | 18.5 (27) | 24.3 (73) | 22.4 (100) | 0.37 | 0.79 | 0.47-1.32 |
A*23 | 33.6 (49) | 31.3 (94) | 32.1 (143) | 0.69 | 1.09 | 0.70-1.70 |
A*26 | 16.4 (24) | 13.7 (41) | 14.6 (65) | 0.28 | 1.37 | 0.77-2.44 |
A*30 | 24.6 (36) | 17.3 (52) | 19.7 (88) | 0.25 | 1.34 | 0.20-2.22 |
A*33 | 38.4 (56) | 39.0 (117) | 38.8 (173) | 0.98 | 1.01 | 0.66-1.54 |
A*68 | 17.8 (26) | 14.3 (43) | 15.5 (69) | 0.32 | 1.33 | 0.76-2.32 |
A*74 | 6.9 (10) | 12.3 (37) | 10.5 (47) | 0.02 | 0.39 | 0.18-0.83 |
B*07 | 4.9 (7) | 7.0 (16) | 6.2 (23) | 0.30 | 0.61 | 0.24-1.55 |
B*08 | 26.8 (38) | 14.8 (34) | 19.4 (72) | 0.003 | 2.27 | 1.32-3.90 |
B*13 | 5.6 (8) | 5.7 (13) | 5.7 (21) | 0.80 | 1.13 | 0.44-2.89 |
B*14 | 9.9 (14) | 8.3 (19) | 8.9 (33) | 0.75 | 1.13 | 0.53-2.39 |
B*15 | 38.7 (55) | 45.2 (104) | 42.7 (159) | 0.11 | 0.69 | 0.44-1.08 |
B*18 | 6.3 (9) | 4.4 (10) | 5.1 (19) | 0.64 | 1.26 | 0.48-3.33 |
B*35 | 14.1 (20) | 21.3 (49) | 18.6 (69) | 0.10 | 0.61 | 0.34-1.11 |
B*44 | 5.6 (8) | 5.2 (12) | 5.4 (20) | 0.79 | 1.14 | 0.43-2.98 |
B*49 | 14.1 (20) | 13.5 (31) | 13.7 (51) | 0.88 | 0.95 | 0.51-1.79 |
B*53 | 16.2 (23) | 23.9 (55) | 21.0 (78) | 0.09 | 0.62 | 0.35-1.08 |
B*58 | 22.5 (32) | 18.7 (43) | 20.2 (75) | 0.19 | 1.43 | 0.84-2.46 |
Cw*01 | 9.0 (13) | 6.9 (19) | 7.6 (32) | 0.34 | 1.45 | 0.67-3.11 |
Cw*02 | 15.2 (22) | 21.1 (58) | 19.1 (80) | 0.17 | 0.68 | 0.39-1.19 |
Cw*03 | 40.0 (58) | 44.7 (123) | 43.1 (181) | 0.46 | 0.85 | 0.56-1.30 |
Cw*04 | 29.7 (43) | 30.2 (83) | 30.0 (126) | 0.51 | 0.86 | 0.54-1.36 |
Cw*05 | 8.3 (12) | 4.4 (12) | 5.7 (24) | 0.37 | 1.49 | 0.62-3.58 |
Cw*06 | 7.6 (11) | 9.8 (27) | 9.1 (38) | 0.64 | 0.83 | 0.39-1.78 |
Cw*07 | 38.6 (56) | 33.1 (91) | 35.0 (147) | 0.10 | 1.46 | 0.94-2.27 |
Cw*08 | 13.8 (20) | 15.3 (42) | 14.8 (62) | 0.61 | 0.86 | 0.47-1.56 |
Cw*16 | 4.8 (7) | 7.3 (20) | 6.4 (27) | 0.23 | 0.56 | 0.22-1.43 |
“All” represents the percentage of individuals positive for the indicated allele in the community; n, the number of individuals carrying the allele of interest; P, P values uncorrected for multiple comparisons; OR, the odds ratio derived by comparing the number of individuals positive for the indicated allele versus those without the allele between case (HIV-2+) and control (HIV-negative) groups. P values and ORs were calculated by logistic regression, controlling for gender and age. Only alleles with an overall frequency of at least 5% are shown. P values of <0.05 are shown in bold.